Clinical Trial Update: Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on lorlatinib for patients with metastatic ROS1-positive non-small cell lung cancer after failure of first-line TKIs (ALBATROS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING